Reasons and Solutions for Platelet Failure to Elevate with Avatrombopag (Sucoxin)

Avatrombopag is an oral thrombopoietin (TPO) receptor agonist. It promotes platelet production by activating the TPO receptor of bone marrow megakaryocytes. It is mainly used to treat thrombocytopenia and immune thrombocytopenia (ITP) in patients with chronic liver disease. In most patients, it can effectively increase platelet levels and provide safety for surgery or invasive procedures.

Some patients do not see a significant increase in platelets after using avatrombopag. The reasons may include:① The persistence of primary disease factors, such as impaired bone marrow hematopoietic function or severe liver fibrosis, leading to insufficient expression of TPO receptors; ② Poor medication compliance, failure to take medication regularly as prescribed or insufficient dosage; ③ Interference from combined medication, such as the use of certain chemotherapy drugs or immunosuppressants that affect bone marrow function; ④ Individual differences, some patients have low response to TPO receptor agonists and are less sensitive to stimulation of platelet production.

In the case where platelets are not elevated, the following measures can be taken:①Adjust the dose according to the doctor's advice and gradually increase the dose within a safe range to improve the efficacy; ②Optimize the medication plan to ensure regular medication and avoid missing doses or reducing the dose on your own; ③Evaluate combined medications to minimize drugs that interfere with bone marrow hematopoiesis, and monitor liver function and blood routine; ④If necessary, combine with other supportive treatments, such as platelet transfusion or correction of nutritional deficiencies to enhance bone marrow hematopoietic function.

During the use of avatrombopag, platelet levels should be monitored regularly, the drug efficacy should be observed and the dosage should be adjusted in a timely manner. At the same time, the patient's underlying diseases and comorbidities should be assessed to identify factors potentially leading to insufficient platelet elevation. For patients who have an inadequate response to drugs, an individualized treatment plan should be selected under the guidance of a specialist, combined with dose adjustment and supportive therapy, to achieve a safe increase in platelet levels and reduce the risk of bleeding.

Reference materials:https://www.drugs.com/